Multiple sclerosis : clinical and laboratory research
-
Controlled Clinical Trial
Interferon beta therapy increases serum ferritin levels in patients with relapsing-remitting multiple sclerosis.
Serum ferritin levels have been found to be increased in patients with active progressive multiple sclerosis (MS). However, its levels are reported to be unchanged in stable and in active relapsing-remitting (RR) form of the disease. No research to date has assessed the influence of interferon beta (IFN-beta) on ferritin concentrations. ⋯ There were no significant differences between controls and patients under stable and untreated conditions. In patients at 12 months after the beginning of IFN-beta therapy, ferritin levels were higher in women and in men, in comparison with baseline (71.4 +/- 58.6 vs 43.4 +/- 29.9 ng/mL, P = 0.0006 and 216.0 +/- 124.3 vs 127.8 +/- 74.9 ng/mL, P = 0.0022, respectively). These results suggest that larger prospective studies are required to evaluate the role of serum ferritin in MS and its potential usefulness in monitoring responses to immunomodulatory therapies.
-
Many patients referred to multiple sclerosis (MS) centers with symptoms suggestive of MS are found to have normal neurologic examinations, normal or non-specific brain magnetic resonance imaging (MRI) scan findings, and normal cerebrospinal fluid (CSF). Persistent symptoms often lead to multiple consultations and repeated diagnostic investigations. We performed a study to evaluate the diagnostic utility of repeated evaluations in patients with normal initial assessments and persistent neurologic symptoms. ⋯ and clinicians may be reassured that persistent neurologic symptoms in the absence of objective clinical evidence do not lead to the development of MS. Costly serial investigations should be carefully considered, particularly in the presence of normal neurologic examination at follow-up.
-
Magnetization transfer (MT) magnetic resonance imaging (MRI) can provide quantitative information about the severity of tissue damage in the cervical cord of patients with multiple sclerosis (MS). MT MRI-derived measures of cord damage are correlated with the severity of disease-related locomotor disability. ⋯ Cervical cord tissue damage seems to be limited to macroscopic lesions in patients with early, non-disabling RR MS. Longitudinal studies are warranted to define the dynamics of MS-related cord damage accumulation over time later on in the course of the disease.